Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214
- PMID: 12499169
- PMCID: PMC149009
- DOI: 10.1128/AAC.47.1.54-61.2003
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214
Abstract
Zidovudine resistance (ZDV-R) is associated with classic genotypic changes at codons 41, 67, 70, 210, 215, and 219 of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) gene as well as with the multinucleoside resistance (MNR) complexes (Q151M MNR complex; 6-bp insertion/A62V complex). In addition, enhanced resistance to ZDV in the context of the classic ZDV mutations plus the M184V mutation has been associated with additional mutations at positions 208, 211, 214, and 333. In this study we investigated phenotypic ZDV-R determined by a recombinant virus assay (Antivirogram; Virco) in 223 clinical samples in relation to the above genotypic changes. 150 out of 223 clinical samples had the M184V mutation. Phenotypic ZDV-R ranged from 0.3- to 5,338-fold. Sixteen samples (15 with high ZDV-R ranging from 90- to 3,571-fold) contained MNR-associated patterns. Analysis of classic mutational patterns broadly demonstrated increasing ZDV-R with increasing number of ZDV mutations. A comparable correlation was obtained when ZDV-R was analyzed only relative to the T215Y/F mutation. Site-directed mutagenesis experiments investigating the influence of the additional mutations H208Y, R211K, and L214F on ZDV-R resulted in a 7.4- or 21-fold increase in ZDV-R when the R211K/L214F or H208Y/R211K/L214F mutations, respectively, were added to a highly ZDV-R virus. In the clinical sample data set we analyzed, the combination of R211K/L214F appeared most frequently. The H208Y change was detected only in highly ZDV-R viruses, whereas the G333E/D change was distributed equally. All changes were independent of the M184V mutation. A 2.4- or 8-fold increase in ZDV-R was observed in the clinical samples with high ZDV-R containing the R211K/L214F or H208Y/R211K/L214F mutations, respectively. We have shown that the combination of the additional mutations H208Y, R211K, and L214F in HIV-1 RT may influence ZDV-R and should be considered when assessing ZDV-R.
Figures






Comment in
-
Human immunodeficiency virus polymorphisms and zidovudine resistance.Antimicrob Agents Chemother. 2003 Aug;47(8):2714; author reply 2714-5. doi: 10.1128/AAC.47.8.2714-2715.2003. Antimicrob Agents Chemother. 2003. PMID: 12878551 Free PMC article. No abstract available.
Similar articles
-
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.Antimicrob Agents Chemother. 2007 Nov;51(11):3861-9. doi: 10.1128/AAC.00646-07. Epub 2007 Aug 27. Antimicrob Agents Chemother. 2007. PMID: 17724152 Free PMC article.
-
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.J Clin Virol. 2000 Dec;19(3):135-42. doi: 10.1016/s1386-6532(00)00087-1. J Clin Virol. 2000. PMID: 11090748
-
A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.Antivir Ther. 2002 Jun;7(2):131-9. Antivir Ther. 2002. PMID: 12212925
-
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.J Virol. 2006 Jul;80(14):7020-7. doi: 10.1128/JVI.02747-05. J Virol. 2006. PMID: 16809307 Free PMC article.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
Cited by
-
Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C.PLoS One. 2012;7(10):e46622. doi: 10.1371/journal.pone.0046622. Epub 2012 Oct 3. PLoS One. 2012. PMID: 23056372 Free PMC article.
-
Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.AIDS Res Hum Retroviruses. 2011 Jan;27(1):71-80. doi: 10.1089/aid.2010.0050. Epub 2010 Oct 21. AIDS Res Hum Retroviruses. 2011. PMID: 20964479 Free PMC article.
-
Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):e26-7. doi: 10.1097/QAI.0b013e31823e2d2b. J Acquir Immune Defic Syndr. 2012. PMID: 22245718 Free PMC article.
-
Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.J Gen Virol. 2013 Oct;94(Pt 10):2297-2308. doi: 10.1099/vir.0.054999-0. Epub 2013 Jun 26. J Gen Virol. 2013. PMID: 23804564 Free PMC article.
-
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Nucleic Acids Res. 2016 Mar 18;44(5):2310-22. doi: 10.1093/nar/gkw060. Epub 2016 Feb 4. Nucleic Acids Res. 2016. PMID: 26850643 Free PMC article.
References
-
- Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (−) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234. - PMC - PubMed
-
- Chen, P., J. C. Schmit, V. Arendt, J. M. Plesseria, C. Lambert, E. Fontaine, P. Kirpach, D. Ninove, F. Schneider, and R. Hemmer. 1997. Drug resistance mutations as predictors of phenotypic zidovudine resistance in HIV-1 infection. AIDS 11:1528-1529. - PubMed
-
- De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903. - PubMed
-
- De Jong, J. J., J. Goudsmit, V. V. Lukasov, M. E. Hillebrand, E. Baan, R. Huismans, S. A. Danner, J. H. Ten Veen, F. De Wolf, and S. Jurriaans. 1999. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13:75-80. - PubMed
-
- Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, and The ZDV Collaborative Working Group. 1987. The efficacy of azidothymidine (ZDV) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:185-191. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources